Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma
← catalyst calendarSponsored by Innate Pharma (industry) · IPH.PA — their whole pipeline →.
Phase
Phase 1/2
Status
Terminated
Study type
Interventional
Design
Na · None · Treatment
Enrollment
23actual
Sites
14
Countries
Australia, France, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Following Completion of dose escalation, the study has been discontinued as part of the Company's strategic priorization of its pipeline.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-03-04 | actual | When the study began enrolling |
| Primary completion | 2026-02-06 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-02-06 | actual | The whole study's end, after follow-up |
| First posted | 2023-10-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non Hodgkin Lymphoma
Intervention
- Drug: IPH6501
Primary outcome
what the primary-completion date above is the date OFSafety and tolerability
measured From time of informed consent through treatment period and including the follow-up: up to 22 months
Permalink · IPH.PA's whole pipeline · Catalyst calendar · Every registered study · What changed